What question did this study set out to answer?

This research aims to develop a framework for disease progression in multi-scale environments, particularly for chronic conditions.

June 23, 2026Open Access

Compound Race Pathology: A Friction-Theoretic Framework for Multi-Scale Disease Progression and Intervention

Key Points

This research aims to develop a framework for disease progression in multi-scale environments, particularly for chronic conditions.
Proposed a friction-theoretic model for compound race pathology across various diseases.
Extended metabolic control analysis to capture multi-scale disease progression.
Operationalized case examples include rheumatoid arthritis and heart failure, with empirical predictions for testing.
Identified chronic multi-system dysregulation as a common feature across diseases, suggesting single-target therapies are inadequate.
Demonstrated the need for multi-scale intervention approaches due to inter-individual heterogeneity and treatment response patterns.
Established testable predictions for validating the proposed framework with specific intervention strategies.

Abstract

Cancer is rarely one button pressed; it is a series of small steps, which is why drug combinations beat single drugs. This paper proposes that this shape, many small steps adding up with no single one in control, is the shared form behind a whole group of conditions. It is a framework-theoretic account of compound disease progression and intervention, applying the Friction Theory architecture (Pødenphant Lund 2026b, Paper 1) to cancer, autoimmune disease, ME/CFS and long COVID, and treatment-resistant depression as instances of compound multi-scale race pathology. Target venue: Cell Reports Medicine (primary); fallbacks PLOS Medicine, Nature Communications. Abstract. Several major chronic and progressive diseases share a clinical signature that single-mechanism explanations have struggled to capture: chronic multi-system dysregulation that responds poorly to single-target therapy, presents with substantial inter-individual heterogeneity, and produces episodic exacerbations or treatment-failure patterns that cannot be reduced to any one pathway. We propose that these conditions are framework-distinct instances of compound race pathology: disease progression produced by coupled multi-scale RACE-architectures where each contributing scale resolves its own race under commit-pressure, hysteretic trace accumulates across scales, and the compound mechanism cannot be addressed by intervention bounded at any single scale's control coefficient. Central formal apparatus. The paper extends Metabolic Control Analysis (Kacser Heinrich the framework specifies (a) progression-rate as the conserved scalar additive by hysteretic-trace deposition, (b) control coefficients per scale operationalised via factorial design where data permit, (c) linear-response approximation valid in the linear regime, with (d) modified formalism (non-linear interaction terms; cascade percolation per Buldyrev et al. 2010; Hill-equation saturation) for the three non-linear regimes specified in §2.3. Worked-example operationalisation candidates: rheumatoid arthritis (RA, O'Dell triple-DMARD anchor) and heart failure with reduced ejection fraction (HFrEF, included as an applicability-mapping case outside the framework's construction-set in §3.5, with COPD triple-therapy and T2DM combination-therapy registered as the genuinely adversarial forward tests). Hysteresis-fighting taxonomy. Three categories distinguish wholesale attractor-perturbation interventions by durability profile, with sub-classification by substrate-reversibility: A1 cellular reversible (HSCT MS, FMT for recurrent C. difficile, CAR-T SLE drug-free remission); A2 mixed (HSCT SSc, CAR-T IIM); A3 fibrotic halt-only (CAR-T SSc no-progression). Empirically anchored on the CASTLE 2026 SLE/IIM/SSc gradient (Müller et al. 2026, Nature Medicine). Category B (substrate-modification with consolidation requirement): ketamine + CBT (Wilkinson 2017/2021), psilocybin-assisted TRD (Carhart-Harris 2021), HBOT for long COVID. Category C (state-perturbation requiring maintenance): SSRI/SNRI, esketamine, ECT without continuation. Ten empirical predictions plus R1–R10 falsification set with explicit framework-pivotal vs component-test distinction. R3 (substrate-vector predicts response in compound disease) and R5 (CAR-T SLE/IIM/SSc substrate-reversibility gradient at n ≥ 100) are pre-committed as framework-pivotal: their joint disconfirmation refutes the framework's central compound-multi-scale-RACE mechanism; no graceful-degradation clause permits joint survival. R1, R2, R4, R6–R10 are component-tests: their disconfirmation forces revision of specific framework components while the central mechanism is preserved. Substrate-vector stratification and coupling-across-scales. The framework acknowledges that multi-axis biomarker stratification is established in precision medicine (Tsimberidou 2020 review; PAM50; OncoType DX; FoundationOne CDx). The framework's distinct contribution is the coupling-across-scales component: the six TRD axes (inflammation, HPA, microbiome, cognitive pattern, behavioural activation deficit, sleep substrate) are framework-predicted to be coupled via cross-scale commit-pressure transmission, with intervention at one axis producing secondary modification at coupled axes within timescales characteristic of cross-scale propagation. This is operationally testable as cross-axis longitudinal correlation under single-axis intervention, distinguishing substrate-vector stratification from precision-medicine single-axis stratification. Framework-distinction from Allostatic Load, network medicine, and critical-transitions theory demonstrated via worked example: a 55-year-old patient with top-quintile AL score and single dominant B12 rate-limiting node — AL prescribes multi-system intervention; the framework prescribes single-target B12 supplementation with cross-axis re-measurement at 12 weeks. The two prescriptions diverge sharply and generate different empirical predictions about clinical trajectory. The framework adds a distinct operational layer rather than displacing existing traditions. Author position and invitation. The author is an independent researcher without clinical credentials in oncology, immunology, post-viral medicine, or treatment-resistant depression neurobiology. The framework is positioned as hypothesis-and-invitation: it specifies what to test rather than what to prescribe. Domain-expert collaboration is explicitly invited for the worked-example operationalisations (RA, HFrEF), the multi-axis biomarker-panel development, and the prospective tests of R3 and R5. Companion papers in the Friction Theory series: Paper 8 (Psychiatric Clinical Intervention): 10.5281/zenodo.20059866 (reserved) Paper 8c (Translational Research-Programme): 10.5281/zenodo.20059872 (reserved) Paper 8d (Sub-threshold Cofactor Support): 10.5281/zenodo.20277291 (reserved) Paper 0 (Behavioural Friction Theory): 10.5281/zenodo.19462499 Paper 1 (Friction Theory substrate): 10.5281/zenodo.20012654 Series project page: frictiontheory.org. ORCID: 0009-0000-4724-2427. Paper 8b in the Friction Theory paper-series.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper